Megafine must investigate data faking at banned API plant says US FDA

By Gareth Macdonald contact

- Last updated on GMT

Megafine's response to Form 483 inadequate says US FDA (image: Megafine website)
Megafine's response to Form 483 inadequate says US FDA (image: Megafine website)

Related tags: Pharmaceutical drug, Food and drug administration, Fda

The US FDA has told Megafine Pharma it must determine the extent of data falsification at the plant in Nashik, Maharashtra that was banned from shipping APIs to the US last year.

The US regulator called for an investigation in a letter​ sent to Megafine last month, explaining that the firm’s response to an earlier Form 483 detailing evidence of stability data falsification was ‘inadequate​.’

In your response, you stated that laboratory management did not discover the discrepancy until the 24-month stability interval. You also stated that the batch quality is unaffected because subsequent test results met specifications at the 24-month and 36-month stability intervals.

Your response is inadequate because it does not address the extent of the data falsification that could exist in your laboratory.

The agency added that: “You have not provided the results of any investigation to determine the accuracy of the test data for other batches of drugs and the corrective actions that should be implemented to ensure the quality of the drugs intended for U.S. distribution​.”

Remediation 

The US Food and Drug Administration (FDA) said Megafine needs to investigate extent of the inaccuracies in data records and reporting and ask a third party to interview current and former employees about data management practices.

The agency also said Megafine management need to put together a corrective action plan and provide details of measures that will prevent data falsification in the future.

The Nashik facility has been banned from supplying active pharmaceutical ingredients (APIs) since October last year when Megafine was placed on the agency’s import alert.

Megafine will remain on the list of firms banned from shipping APIs to the US until it complies with the FDA's request.

The firm, which still lists the Nashik facility as being accredited by the US FDA on its website, did not respond to a request for comment.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars